Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04754100 · ClinicalTrials.gov registry record · Phase 1
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by MiNK Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT04754100 is a Phase 1 study that has completed, run by MiNK Therapeutics. The registered enrollment target is 13 participants.
The verdict
NCT04754100, a Phase 1 study, has completed, sponsored by MiNK Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed or refractory multiple myeloma, as well as to define the recommended Phase 2 dose.
Interventions
- DRUG agenT-797
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-03-29 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04754100
The ClinicalTrials.gov registry entry for NCT04754100 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MiNK Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which agenT-797 is the first listed.
NCT04754100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04754100 about?
NCT04754100 is a clinical study titled "agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma". This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed or refractory multiple myeloma, as well as to define the recommended Phase 2 dose.
What is the current status of trial NCT04754100?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-03-29. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT04754100?
The interventions under investigation include: agenT-797 (DRUG).
Who is sponsoring clinical trial NCT04754100?
This trial is sponsored by MiNK Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.